Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017-2019.
In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%-82% among participants with available viral load data and 63%-65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.
Authors
Abdullahi Abdullahi, Martin Martin, Kwabena Kwabena, Wisso Abdullahi Wisso Abdullahi, Kida Kida, Osawe Osawe, Onyemata Onyemata, Aliyu Aliyu, Charurat Charurat, Ibrahim Ibrahim, Adamu Adamu, Omuh Omuh, Efuntoye Efuntoye, Dakum Dakum, Abimiku Abimiku, Gupta Gupta
View on Pubmed